Amyloid

San Diego Alzheimer's Partners Come Together

Retrieved on: 
星期一, 三月 18, 2024
Research, Partner, Aisén, Brain, MRI, Disease, CSF, SHARP, Diabetes, SAN, PET, Cerebrospinal fluid, Molina Healthcare, ACTC, Blood, Collection, Dementia, Amyloid, CBS 8

SAN DIEGO, March 18, 2024 /PRNewswire/ -- The Alzheimer's Therapeutic Research Institute (ATRI) and over a half-dozen of San Diego's Alzheimer's partners invite the community to a free event on March 23, 2024. A Day of SCervice, in support of accelerating Alzheimer's disease (AD) research through blood testing. Though the entire San Diego community is invited to visit ATRI and learn about new advances in AD research, those attending who are over the age of 55 and interested in participating in AD clinical trials can consent and, if eligible, have their blood drawn that day.

Key Points: 
  • SAN DIEGO, March 18, 2024 /PRNewswire/ -- The Alzheimer's Therapeutic Research Institute (ATRI) and over a half-dozen of San Diego's Alzheimer's partners invite the community to a free event on March 23, 2024.
  • Local CBS 8 news anchor and Alzheimer's San Diego Board Chair, Carlo Cecchetto, will moderate the morning panel.
  • "March 23 is also Day of SCervice, and the San Diego Trojan Family will be making a difference," said Shelley Moore, President-Elect of the San Diego Trojan League of San Diego County.
  • These clinical trials are vital to the work we do," said Janet Hamada-Kelley, Executive Director of the Alzheimer's Association San Diego & Imperial County an one of the event partners.

Beckman Coulter and Fujirebio Expand Partnership to Develop Patient-friendly, Blood-based Neurodegenerative Disease Diagnostics

Retrieved on: 
星期二, 三月 12, 2024
Neurodegenerative disease, Health, Fujirebio, DirectX, Partnership, Patient, Biomarker, Research, RUO, IVD, Beckman Coulter, Apolipoprotein E, Analyser, Therapy, Physician, AFL, Amyloid

BREA, Calif. and TOKYO, March 12, 2024 /PRNewswire/ -- Beckman Coulter Diagnostics, a clinical diagnostics leader, and Fujirebio, a leader in neurological markers and In Vitro Diagnostic (IVD) manufacturing, today announced an expansion of their partnership focused on development, manufacturing and clinical adoption of neurodegenerative disease assays.

Key Points: 
  • BREA, Calif. and TOKYO, March 12, 2024 /PRNewswire/ -- Beckman Coulter Diagnostics, a clinical diagnostics leader, and Fujirebio, a leader in neurological markers and In Vitro Diagnostic (IVD) manufacturing, today announced an expansion of their partnership focused on development, manufacturing and clinical adoption of neurodegenerative disease assays.
  • In 2023, Beckman Coulter and Fujirebio entered into a collaboration agreement focused on new biomarkers aligned with recently approved monoclonal antibody-based Alzheimer's disease therapeutics.
  • Kevin O'Reilly, President, Beckman Coulter Diagnostics, commented, "We are very excited by our expanded partnership with Fujirebio designed to overcome challenges of developing highly sensitive assays, measuring ultra-low concentrations of neurodegenerative disease biomarkers circulating in the blood stream."
  • "Our expanded partnership with Beckman Coulter will enable increased laboratory, clinician and patient access to more neurodegenerative biomarkers around the world," stated Monte Wiltse, President & CEO, Fujirebio Diagnostics, Inc. "We look forward to continued collaboration with Beckman Coulter bringing these critical assays to physicians and patients worldwide."

Biogen Highlights New Data at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™) 2024 Annual Meeting

Retrieved on: 
星期一, 三月 4, 2024
OGA, Research, BIIB, Investment, Eisai, Alpha-synuclein, Amyloid, Conference, Biogen, Quantitative systems pharmacology, Dementia, MCI, QSP, Clarity, MAPT, Brain, Vaccine

The presentations include new data for its oral small molecule inhibitor of tau aggregation (BIIB113), as well as presentations providing insights into the underlying mechanisms of Alzheimer’s disease.

Key Points: 
  • The presentations include new data for its oral small molecule inhibitor of tau aggregation (BIIB113), as well as presentations providing insights into the underlying mechanisms of Alzheimer’s disease.
  • In addition to BIIB113, Biogen is researching the potential of tau reduction in AD with its investigational antisense oligonucleotide targeting the microtubule associated protein tau (MAPT) gene (BIIB080).
  • Oral presentation: Results of the first in-human, randomized, blinded, placebo-controlled, single- and multiple-ascending dose study of BIIB113 in healthy volunteers.
  • Oral presentation: Lecanemab for the treatment of early Alzheimer’s disease; the extension of efficacy results from Clarity AD.

Neurologists Report Frustration with Efficacy and Logistical Issues Around Eisai/Biogen’s Leqembi, According to Spherix Global Insights Neurologist Survey

Retrieved on: 
星期四, 二月 22, 2024
DMT, CMS, ARIA, Friends, Neurology, Amyloid, Risk, Safety, DMTS, Medicare, Patient, Launch, Insurance, Benchmarking, Learning, PET, Brain, Pharmaceutical industry

Spherix Global Insight’s January update from their Launch Dynamix™: Leqembi in Alzheimer’s Disease (US) service sheds light on neurologists’ early reactions to Leqembi.

Key Points: 
  • Spherix Global Insight’s January update from their Launch Dynamix™: Leqembi in Alzheimer’s Disease (US) service sheds light on neurologists’ early reactions to Leqembi.
  • Analysis from 75 high-prescribing U.S. neurologists reveals the potential reasons behind the even slower-than-expected adoption of Leqembi for treatment of early AD.
  • Six months after the full commercial launch of Leqembi, few surveyed neurologists consider Leqembi to be a significant medical advance over other historical AD treatments.
  • For all these reasons, Spherix will continue tracking neurologists’ attitudes and use of DMTs in AD well into the future.

MHRA Issues Notice of Acceptance for POLARIS-AD, a Phase 3 Early Alzheimer’s Disease Trial Sponsored by AriBio Co., Ltd.

Retrieved on: 
星期日, 二月 25, 2024
Nursing, Biotechnology, Practice Management, Health, General Health, Pharmaceutical, Neurology, Other Science, Medical Devices, Science, Clinical Trials, EMA, FDA, Food, Mirodenafil, Amyloid, Safety, Biomarker, European Medicines Agency, GDS, POLARIS, Patient, MHRA, CSF, Clinical trial, Plasma, Medication, Pharmaceutical industry

AriBio Co., Ltd. (AriBio) receives Notice of Acceptance for POLARIS-AD, a Phase 3 early Alzheimer’s disease clinical trial from the Medicines and Healthcare Products Regulatory Agency (MHRA) in the United Kingdom (UK).

Key Points: 
  • AriBio Co., Ltd. (AriBio) receives Notice of Acceptance for POLARIS-AD, a Phase 3 early Alzheimer’s disease clinical trial from the Medicines and Healthcare Products Regulatory Agency (MHRA) in the United Kingdom (UK).
  • The MHRA completed their review on the 21 of February and confirmed a favorable ethical opinion, the Company expects to initiate the clinical trial before the end of Q1’2024 in the UK.
  • POLARIS-AD is a double-blind, randomized, placebo-controlled, multi-center registration trial to evaluate the efficacy and safety of AR1001 (Mirodenafil) over 52 weeks of treatment in patients with early Alzheimer’s disease.
  • “Acceptance of the POLARIS-AD clinical study in the UK is another achievement in the development of AR1001.

EISAI INVESTS IN C2N TO SUPPORT SIMPLIFYING THE DIAGNOSIS OF EARLY ALZHEIMER'S DISEASE TO BETTER SERVE PATIENTS

Retrieved on: 
星期二, 三月 5, 2024
Collection, Senior, Alzheimer's disease, Pathology, Cerebrospinal fluid, Eisai, Growth, Amyloid, Headquarters, Clinical, Dementia, Patient, CSF, Diagnosis, PET, Environment, Medical imaging

By investing in C2N, Eisai seeks to support efforts to advance blood-based Aβ diagnostics that are accurate and affordable, providing new options for confirming the presence of Aβ.

Key Points: 
  • By investing in C2N, Eisai seeks to support efforts to advance blood-based Aβ diagnostics that are accurate and affordable, providing new options for confirming the presence of Aβ.
  • "The field of highly accurate blood-based diagnostics is rapidly advancing and expanding," said Keisuke Naito, Global Alzheimer's Disease Officer, Senior Vice President, Eisai.
  • "Given the expense and capacity limitations of PET and CSF tests, Eisai is working to support the dementia ecosystem's growth.
  • The availability of more affordable and minimally invasive diagnostic tools helps support broad access for the management of Alzheimer's disease."

Clinical Use of Blood Biomarkers in the Era of Disease Modifying Treatments for Early Symptomatic Alzheimer's Disease, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
星期二, 三月 5, 2024
LP, Alzheimer's disease, Doctor of Philosophy, MD, Pathology, PET, Cerebrospinal fluid, Diagnosis, Amyloid, Biomarker, DMTS, Deficit spending, Health, Associate, Patient, CSF, Brain, Medical imaging

TORONTO, March 5, 2024 /PRNewswire-PRWeb/ -- The availability of disease-modifying treatments (DMTs) for early symptomatic Alzheimer's disease (AD) has greatly increased the need for clinical AD biomarker testing, which is helpful for determining whether cognitive impairment is caused by AD brain pathology or some other condition. Biomarker evidence of amyloid pathology is essential before the initiation of AD DMTs. This webinar will review the types of AD biomarker tests that are clinically available, including cerebrospinal fluid (CSF) biomarkers, amyloid positron emission tomography (PET) and AD blood tests.

Key Points: 
  • In this free webinar, learn about different Alzheimer's disease (AD) biomarker testing modalities, and the particular promise of high-performance AD blood tests.
  • Attendees will also learn about the variability in the diagnostic performance of AD blood tests and how performance affects the clinical use of tests.
  • This webinar will review the types of AD biomarker tests that are clinically available, including cerebrospinal fluid (CSF) biomarkers, amyloid positron emission tomography (PET) and AD blood tests.
  • Register for this webinar to learn more about different AD biomarker testing modalities, and the particular promise of high-performance AD blood tests.

Stowers Institute Scientific Director Kausik Si receives coveted award from the Chan Zuckerberg Initiative

Retrieved on: 
星期三, 二月 21, 2024
Acquisition, Alzheimer's disease, Thought, Medical research, Neurodegenerative disease, Amyloid, Protein engineering, University, CZI, Memory, Research

KANSAS CITY, Mo., Feb. 21, 2024 /PRNewswire/ -- The Chan Zuckerberg Initiative (CZI) has announced the awardees of their second cycle of Collaborative Pairs Pilot Project Awards, part of the CZI Neurodegeneration Challenge Network (NDCN).

Key Points: 
  • Scientific Director Kausik Si, Ph.D., from the Stowers Institute for Medical Research will receive an award for the project titled, "Tuning memory by altering amyloids," which will be conducted alongside Investigator Lukasz Joachimiak, Ph.D., from the University of Texas Southwestern.
  • The Collaborative Pairs Pilot Project Awards were launched in 2018 to investigate neurodegenerative disease biology by aligning two scientists with diverse expertise.
  • Following the success of the first cycle, the NDCN expanded the research scope beyond neurodegenerative disease, seeking proposals covering broader neuroscience biology.
  • "The award from CZI to Kausik and his collaborator is a nod to the Stowers Institute's focus on spurring discovery and contributing scientific insight into some of the most difficult problems in the life sciences," said Stowers Institute President and Chief Scientific Officer Alejandro Sánchez Alvarado, Ph.D.

Prothena Reports Fourth Quarter and Full Year 2023 Financial Results, and Provides Financial Guidance and Business Highlights

Retrieved on: 
星期四, 二月 15, 2024
Research, FDA, Clinical Trials, Cardiology, Biotechnology, Health, Pharmaceutical, Science, Oncology, Therapy, Fast Track, Acquisition, SAD, VITAL, Roche, American Society of Hematology, ASH, Risk, Food, Epitope, AAIC, ID, Novo Nordisk, Exercise, Organ dysfunction, Amyloidosis, Amyloid, Conference, Bristol Myers Squibb, BMS, Society, TTR, European Medicines Agency, Patient, Clinical trial, ATTR, IND, Orphan, Mortality, Failure, Pharmaceutical industry

In addition, the Company provided 2024 financial guidance and business highlights.

Key Points: 
  • In addition, the Company provided 2024 financial guidance and business highlights.
  • “2023 was a year of strong progress for Prothena as we advanced our protein dysregulation portfolio and moved closer to becoming a fully integrated commercial company.
  • Total revenue for the fourth quarter and full year of 2023 included BMS collaboration revenue of $0.3 million and $91.3 million, respectively.
  • As of December 31, 2023, Prothena had $621.0 million in cash, cash equivalents and restricted cash, and no debt.

Attralus Closes $56 Million Financing

Retrieved on: 
星期二, 二月 6, 2024
AT-02, SAN, Bristol Myers Squibb, PAR, Amyloid, Patient, BMY, Amyloidosis, ATTR, Pharmaceutical industry

SAN FRANCISCO, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Attralus, Inc., a clinical-stage biopharmaceutical company developing transformative medicines to improve the lives of patients with systemic amyloidosis, today announced that it has closed a $56 million financing. The financing round was led by new investor Alpha Wave Ventures and also included Bristol Myers Squibb (BMY). Existing investors also participated including founding investor venBio Partners, Surveyor Capital (a Citadel company), Vivo Capital, Logos Capital and Sarissa Capital Management.

Key Points: 
  • SAN FRANCISCO, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Attralus, Inc., a clinical-stage biopharmaceutical company developing transformative medicines to improve the lives of patients with systemic amyloidosis, today announced that it has closed a $56 million financing.
  • The financing round was led by new investor Alpha Wave Ventures and also included Bristol Myers Squibb (BMY).
  • “With this support, we plan to accelerate our clinical development strategy to advance our portfolio programs.”
    Attralus intends to use the proceeds from the financing to advance the Phase 1/2 development of Attralus’ lead PAR therapeutic product, AT-02, in ATTR and AL amyloidosis.
  • “We look forward to supporting Attralus as it progresses its programs and Attralus looks towards its next phase of growth.”